Brief: Arcus Biosciences Completes Patient Enrollment In Phase 3 Trial Evaluating A Domvanalimab-Containing Regimen In First-Line Metastatic Upper GI Cancers
10/06/2024 13:54
June 10 (Reuters) - Arcus Biosciences Inc RCUS.N :
* ARCUS BIOSCIENCES COMPLETES PATIENT ENROLLMENT IN PHASE 3
TRIAL
EVALUATING A DOMVANALIMAB-CONTAINING REGIMEN IN FIRST-LINE
METASTATIC UPPER GI CANCERS
* ARCUS BIOSCIENCES INC: DOMVANALIMAB PLUS ZIMBERELIMAB AND
CHEMOTHERAPY REGIMEN WAS GENERALLY WELL TOLERATED
* ARCUS BIOSCIENCES INC: NO UNEXPECTED SAFETY SIGNALS WERE
OBSERVED AT TIME OF DATA CUTOFF, MARCH 12, 2024
Source text for Eikon: ID:nBw2WqWbta
Further company coverage: RCUS.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcus Biosciences
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Arcus Biosciences tumbles on $250 mln share sale
Brief: Arcus Biosciences Announces Pricing Of $250 Million Public Offering Of Common Stock
Arcus Biosciences drops after starting stock offering